6 results
This study is intended to establish a dose response rate of MR30507/09 with respect to respiratory effects compared to MR30365/07, fentanyl and placebo..
The primary objective of the study is:• To evaluate the clinical efficacy of rozanolixizumab as a treatment for subjects with CIDPThe secondary objectives of the study are:• To evaluate the safety and tolerability of rozanolixizumab sc infusion in…
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in…
CIDP04 is a Phase 2A, multicenter, single-arm, open-label study with the primary objective of evaluating the long-term safety and tolerability of rozanolixizumab when administered as weekly subcutaneous (sc) infusion in subjects with CIDP. The…
• To assess the efficacy of rozanolixizumab as measured by seizure freedom• To assess the efficacy of ozanolixizumab as measured by change in cognitive function• To assess the efficacy of ozanolixizumab as measured by use of rescue medication• To…
The aim of this prospective single-arm phase II study is to evaluate the efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFRTKI (osimertinib or lazertinib), for patients with EGFR-mutant advanced NSCLC,…